Cite as: 563 U. S. ____ (2011)

1

Opinion of the Court
NOTICE: This opinion is subject to formal revision before publication in the
preliminary print of the United States Reports. Readers are requested to
notify the Reporter of Decisions, Supreme Court of the United States, Wash­
ington, D. C. 20543, of any typographical or other formal errors, in order
that corrections may be made before the preliminary print goes to press.

SUPREME COURT OF THE UNITED STATES
_________________

No. 09–1273
_________________

ASTRA USA, INC., ET AL., PETITIONERS v. SANTA 

CLARA COUNTY, CALIFORNIA 

ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF 

APPEALS FOR THE NINTH CIRCUIT

[March 29, 2011] 


JUSTICE GINSBURG delivered the opinion of the Court.
Section 340B of the Public Health Services Act, 42
U. S. C. A. §256b (Oct. 2010 Supp.), imposes ceilings on
prices drug manufacturers may charge for medications
sold to specified health care facilities. Those facilities,
here called “340B” or “covered” entities, include public
hospitals and community health centers, many of them
providers of safety-net services to the poor. The §340B
ceiling-price program (340B Program) is superintended by
the Health Resources and Services Administration
(HRSA), a unit of the Department of Health and Human
Services (HHS). Drug manufacturers opt into the 340B
Program by signing a form Pharmaceutical Pricing
Agreement (PPA) used nationwide. PPAs are not transac­
tional, bargained-for contracts. They are uniform agree­
ments that recite the responsibilities §340B imposes,
respectively, on drug manufacturers and the Secretary of
HHS. Manufacturers’ eligibility to participate in state
Medicaid programs is conditioned on their entry into PPAs
for covered drugs purchased by 340B entities.
It is conceded that Congress authorized no private right

